RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results
PR Newswire•30/09/2026•16:05 ET
1
Whiz Insights
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results PR Newswire
Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota(®) and Clenpiq(®), two established FDA-approved gastrointestinal (GI) brands that generated $37.5 million in 2025 net sales under Ferring Pharmaceuticals ("Ferring"), an advanced late-stage pipeline and a fully-controlled commercial infrastructure with capacity for portfolio expansion
Get started
Create a free account to read the full story.